Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD

Crinecerfont (Crenessity) has demonstrated substantial and sustained reductions in glucocorticoid doses among adults with 

classic congenital adrenal hyperplasia (CAH)

, according to 2-year data from the CAHtalyst Adult study.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, by Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan.

“Glucocorticoids are not a good thing to be taking chronically – yes, you need them to survive, but you don’t really need them overnight,” Auchus told 

 in an exclusive interview. “What crinecerfont did was allow us to reduce the dose and put it in a more physiological regime, front-loading it in the morning, allowing them to have a circadian rhythm, and maintaining disease control at a level that the endocrinologist in the trial felt was appropriate for that patient.”

Crinecerfont, a selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, functions by reducing and controlling excess adrenocorticotropic hormone and adrenal antigens. It was first approved by the US Food and Drug Administration (FDA) in December of 2024 for the treatment of CAH in conjunction with glucocorticoids among adults and children ≥4 years.

CAHtalyst Adult was a randomized, double-blind, placebo-controlled phase 3 study evaluating crinecerfont in adults with classic CAH. It consisted of a 24-week randomized period during which patients were assigned to either crinecerfont or placebo, followed by 1 year of active treatment with crinecerfont. Patients were then given the option to participate in an open-label extension period, which is projected to last for roughly 3 years.

Patients were eligible for the study if they had a medically confirmed CAH diagnosis due to 21-hydroxylase deficiency and were on a stable steroid regimen. Patients with a diagnosis of any other known form of classic CAH, a history of bilateral adrenalectomy, hypopituitarism, or other conditions requiring chronic glucocorticoid therapy, or a clinically significant unstable medical condition or chronic disease aside from CAH, among other criteria, were excluded from the trial.

The present data highlights 2-year data from the open-label extension – by month 24, 69% of the participants (103/149) had achieved a physiologic glucocorticoid dose of ≤11 mg/m2/day of hydrocortisone equivalents. Additionally, many participants had eliminated nonphysiologic glucocorticoid types altogether. Among the patients initially taking dexamethasone (n = 20), 75% shifted to a dexamethasone-free regimen, while 62% (37/60) taking >2 doses of hydrocortisone per day were able to eliminate a dose.

Auchus also highlighted the significant retention throughout the open-label extension: >80% of patients were still taking crinecerfont at 2 years with no new safety signals detected.

“CAH is a chronic disease, and there’s a lot of disease burden for these patients,” Auchus said. “We want them to be able to just take their medicine and get on with their lives and not worry about things. I think that high retention rate tells you that people are on board with this system.”

Editors’ Note: Auchus reports disclosures with Adrenas Therapeutics, Corcept, Crinetics, Neurocrine Biosciences, Recordati, Astellas, and others.

Bancos I, Hamidi O, Kiefer F, et al. Adults With Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study. Presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Neurocrine Biosciences, Inc. Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia. 

. April 22, 2026. Accessed April 24, 2026. 

https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia-302749451.html

Iapoce C. FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia. 

. December 13, 2024. Accessed April 24, 2026. 

https://www.hcplive.com/view/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia

Neurocrine Biosciences. Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst). ClinicalTrials.gov Identifier: NCT04490915. Updated February 5, 2025. Accessed April 24, 2026. 

https://clinicaltrials.gov/study/NCT04490915

Videos

Auchus discusses the 2-year results from CAHtalyst Adult, highlighting the substantial retention rates over the open-label extension period.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Jagbir Gill, MD, MPH, is an Associate Professor of Medicine in the Division of Nephrology at the University of British Columbia and Medical Director of the Kidney Transplant Program at St. Paul’s Hospital in Vancouver. He also serves as Medical Director of Data and Quality for BC Transplant, President of the Canadian Organ Replacement Register Board of Directors, and as Treasurer for the Canadian Society of Transplantation.

Transplant Care Strategies to Target Mistrust, Close Gaps in Indigenous Communities

Reducing disparities in transplant access for those who reside in Indigenous communities will involve addressing mistrust of the healthcare system, geographic barriers, and making education and resources accessible and patient-centered.

Jagbir Gill, MD, Associate Professor of Medicine in the Division of Nephrology at the University of British Columbia (UBC), shared these common-sense patient-centered solutions to transplant inequities at the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), and then sat down with 

The Residential School System and a Foundation of Mistrust

The residential school system Gill refers to was a government-funded, church-run program in Canada, established in the 19th century, where children from Indigenous families were forcibly removed from their homes. The United States, similarly, implemented “boarding schools” where assimilation tactics and abuses took place.

In his practice, Gill has seen patients who are residential school survivors, along with children and grandchildren of survivors, noting the remaining and significant amount of mistrust in the healthcare system.

“Entering a hospital or clinical environment—which can feel very institutional—can be deeply triggering,” said Gill. “That creates a real challenge when patients are trying to access care that is meant to help or save their lives.”

Approaching Geographic Barriers In Remote/Rural Communities

Often, communities with Indigenous individuals exist in rural or remote areas, outside the breadth of hospitals or healthcare options. Gill’s research revealed that missed appointments were attributed to long-distance transportation hurdles, lost wages, and lack of childcare, not non-adherence.

“As it stands, the model of care for complex services like transplantation is based in large urban hubs and major hospitals. These systems were not designed to meet the needs of patients living in rural and remote regions,” Gill explained. “If we consider the history, the high proportion of Indigenous peoples living in rural and remote areas is not entirely by choice. There has been significant historical displacement, which must also be taken into account.”

One approach to adapting the model of care to these patients' needs is to meet them where they are. This involves bringing resources into communities or making healthcare more accessible through clustered, coordinated transplant workups.

“You have to understand context,” said Gill. “If someone is working as a fisherman and is away for extended periods, that is not non-adherence. If someone misses appointments because they live three and a half hours away or lack phone coverage, that is not non-adherence either.”

Gill gives the example of having a patient come for a week-long stay at a further transplantation center for thorough, pre-planned appointments. By combining these pieces into one trip, this rules out the problem of needing to coordinate multiple trips to transplant centers across multiple dates. Otherwise, virtual care can also be a solution to answering this unmet need.

However, funding remains a key structural part of gaining access to these resources, especially in setting up nurse navigators and coordinating these tests and appointments.

How Storytelling With Community Leaders Can Build Awareness and Trust

When Gill and colleagues were developing their care model, they reached into Indigenous communities for patient-centered recommendations. They found that the existing education materials, which were primarily written, did not “resonate” with patients.

Since oral storytelling is central in Indigenous cultures, Gill and colleagues recognized the broader power of visual storytelling to connect patients with pertinent health information. They developed an education pathway by including prominent Indigenous community members with organ transplantation experience in testimonial videos, to encourage self-advocacy. They even touched on complex topics such as approaching someone about being a living kidney donor.

“Hearing directly from individuals with lived experience—patients who have undergone kidney disease, transplantation, or living donation—is much more powerful than hearing from healthcare workers who are adjacent to that experience,” said Gill. 

What Can Clinicians Do Differently to Support These Populations?

Gill underscores the importance of treating patients with empathy and understanding for their cultural history.


Consolidating transplant workups into single, extended visits to reduce repeated travel.


Using telehealth to reduce geographic barriers where appropriate.


Developing culturally relevant materials with Indigenous storytelling and patient-led video testimonials.


Integrating Indigenous wellness liaisons into care teams to support navigation and identify blind spots.

Team-based care and representation are hugely important, especially having an Indigenous wellness liaison to support patients and serve as an advocate. During activation rounds, they operate as a perspective to help identify blind spots.

“So we have to make decisions about allocation. The key principle is to start with those who need the most support—not necessarily the largest group or the loudest voice, but those with the greatest need,” said Gill. “That is the approach we’ve taken: provide a high standard of support to the highest-need populations first, and then expand from there to other groups who also require assistance but may not require the same level of intensity.”

Editor’s Note: Gill reports no relevant disclosures.

Canadian nephrologist shares common-sense, patient-centered solutions to transplant inequities. EurekAlert! Published April 22, 2026. Accessed April 23, 2026. 

https://www.eurekalert.org/news-releases/1124730

Park K. INDIGENOUS BOARDING SCHOOLS IN THE UNITED STATES AND CANADA: POTENTIAL ISSUES AND OPPORTUNITIES FOR REDRESS AS THE UNITED STATES GOVERNMENT INITIATES FORMAL INVESTIGATION. 

University of Oklahoma College of Law Digital Commons

. Published online 2023. Accessed April 23, 2026. 

https://digitalcommons.law.ou.edu/cgi/viewcontent.cgi?article=1764&context=ailr

Gill describes how storytelling and patient representation can build trust and education in Indigenous populations regarding transplantation. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Scott Isaacs, MD, is an Adjunct Assistant Professor of Medicine at Emory University. He currently serves as Immediate Past President of the American Association of Clinical Endocrinology (AACE).

Prediabetes Isn’t “Watch and Wait”: New Prevention Strategies

Prediabetes has long occupied a gray zone in clinical care, frequently identified but often under-addressed. Traditionally viewed as a precursor to 

 warranting monitoring rather than immediate action, this approach is increasingly being challenged by a growing recognition of the broader cardiometabolic risks associated with early dysglycemia.

Prediabetes should be accurately classified, distinguishing insulin resistance from insulin deficiency, LADA, or secondary endocrine causes.

The “watch and wait” approach is outdated; prediabetes should prompt broader cardiometabolic risk evaluation, including liver, kidney, and cardiovascular health.

Lifestyle modification remains foundational, but incremental, realistic changes and use of pharmacotherapy may be necessary for effective prevention.

Prediabetes should be framed as a reversible condition to encourage patient engagement without causing unnecessary anxiety.

Though not indicated for prediabetes, GLP-1 receptor agonists and related therapies can significantly reduce progression to type 2 diabetes and address associated comorbidities.

Emerging perspectives suggest that prediabetes is not a uniform condition, but rather a heterogeneous state with diverse underlying mechanisms, requiring a more nuanced and proactive clinical strategy. At the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, Scott Isaacs, MD, an adjunct assistant professor of medicine at Emory University and Immediate Past President of AACE, spotlighted this topic in a session on advances in prediabetes and diabetes prevention.

, he emphasized the need for more precise diagnosis and risk stratification. Rather than treating all patients with prediabetes as a single group, he argued that clinicians should evaluate for underlying differences such as insulin resistance, insulin deficiency, or secondary causes including endocrinopathies.

“Prediabetes can sometimes be thought of as a ‘watch and wait’ diagnosis, but that is the wrong way to look at it, because pre diabetes should be a wake up call for cardiometabolic risk,” Isaacs explained.

Beyond glucose abnormalities, prediabetes may signal the presence of conditions such as 

metabolic dysfunction-associated steatotic liver disease

. As such, identification of prediabetes represents an opportunity for comprehensive risk assessment and early intervention aimed at preventing downstream complications.

Lifestyle modification remains the foundation of prevention strategies, but Isaacs acknowledged the real-world challenges of sustained behavioral change. He advocated for a pragmatic approach focused on incremental improvements, such as dietary substitutions, increased physical activity, and gradual adoption of healthier eating patterns.

At the same time, he noted that lifestyle interventions alone may not be sufficient for all patients. In such cases, pharmacologic therapies can play an important adjunctive role in reducing risk and supporting weight management.

Communication is another critical component of effective prediabetes care. Isaacs highlighted the importance of framing the diagnosis in a way that motivates patients without causing undue anxiety. Emphasizing that prediabetes is a reversible condition and that progression to diabetes is not inevitable can help foster engagement and encourage proactive behavior change.

The evolving therapeutic landscape is also reshaping how clinicians approach prevention. The emergence of GLP-1 receptor agonists and related agents has introduced new opportunities to intervene earlier in the disease continuum.

While not formally approved for prediabetes, these therapies have demonstrated substantial efficacy in reducing progression to diabetes and addressing associated comorbidities, including cardiovascular risk and liver disease. As a result, clinical guidelines are increasingly incorporating these agents into prevention-focused strategies.

Editors’ note: Isaacs reports no relevant disclosures.

Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. 

. 2026;32(4):473-518. doi:10.1016/j.eprac.2026.01.006

Salamah HM, Marey A, Abugdida M, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials. 

Isaacs explains how prediabetes care is shifting toward early intervention, risk stratification, and prevention of cardiometabolic disease, not just progression to diabetes.

Type 2 Diabetes

Breaking the ‘Watch and Wait’ Model in Prediabetes Care, With Scott Isaacs, MD

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center.

Crinecerfont and Classic CAH: 2-Year CAHtalyst Results, With Oksana Hamidi, DO

Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency requires lifelong glucocorticoid replacement to suppress adrenocorticotropic hormone (ACTH) and control adrenal androgen excess. The fundamental clinical challenge is that achieving androgen control typically demands supraphysiologic glucocorticoid doses, which carry substantial toxicity. Patients are at risk for exogenous Cushing syndrome, cardiometabolic complications, and reduced quality of life from high-dose, multi-daily regimens.

00:02:29 - Discontinuation of Dexamethasone, Hydrocortisone Reduction

00:03:58 - Long-Term Adherence and Tolerability

00:04:54 - Impact on Downstream CAH Effects

The physiologic replacement range for hydrocortisone is approximately 15 to 20 mg/day, yet many adults with classic CAH are managed on doses nearly double that threshold.

Crinecerfont, a first-in-class corticotropin-releasing factor type 1 (CRF1) receptor antagonist, offers a mechanistically distinct approach. By blocking CRF from activating the CRF1 receptor, crinecerfont reduces ACTH drive and adrenal androgen production, potentially enabling GC dose reduction without sacrificing androgen control. In December 2024, the agent received US Food and Drug Administration approval as an adjunct to physiologic glucocorticoid replacement in classic CAH.

2-year data from the CAHtalyst Adult Study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 by Oksana Hamidi, DO, an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center, extend previously reported findings supporting the FDA approval. The trial enrolled 182 adults taking supraphysiologic glucocorticoid doses at baseline, with a mean daily dose of approximately 32 mg/day. By week 24, crinecerfont-treated participants achieved a least-squares mean glucocorticoid reduction of 27% versus 10% with placebo (LSMD, -17%; 95% CI, -24% to -10%; 

Results showed that reduction was sustained through month 24, with mean glucocorticoid doses stabilizing at approximately 19.4 mg/day (10.6 mg/m²/day). Of note, the proportion of participants achieving a glucocorticoid dose within the physiologic range held at approximately 70% from month 12 through month 24.

Reductions in treatment burden were also documented. Among patients on hydrocortisone with > 2 doses per day, 62% reduced their dosing frequency by ≥ 1 dose per day. Of those on dexamethasone-containing regimens, 75% became dexamethasone-free. Cumulatively, actual glucocorticoid exposure over 2 years was 8010 mg/m² versus a projected 12,152 mg/m² had patients remained on their baseline dose.

“Patients who have classic CAH oftentimes require multiple medications per day, multiple doses per day, so it is a big challenge for them to live on a clock and constantly have reminders on their watches and calendars to keep taking their glucocorticoids, otherwise they lose control of their androgens,” Hamidi explained. “By reducing the doses, say, from 3 times a day dosing to 2 times a day dosing, I strongly believe that that improves patients' overall quality of life, but also their sense about their disease control and allows them to be more consistent with their medication.”

Safety data across the full 2-year period showed no new signals, with most adverse events rated mild or moderate and few discontinuations. Hamidi noted that as glucocorticoid doses are lowered, clinicians should ensure patients are equipped with sick-day guidance and injectable glucocorticoids for adrenal crisis prevention.

The trial's retention rate of > 80% over 2 years reflects sustained patient engagement that Hamidi described as exceeding her expectations and as evidence that patients were seeing the outcomes they had hoped for.

Editors’ note: Hamidi reports relevant disclosures with Corcept Therapeutics, Neurocrine Biosciences, Adaptyx, Camurus, Crinetics Pharmaceuticals, and Recordati Rare Diseases, Inc.

Iapoce C. FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia. HCPLive. December 13, 2024. Accessed April 24, 2026. 

Bancos I, Hamidi O, Kiefer FW, et al. Adults With Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

Hamidi reviews 2-year CAHtalyst data showing crinecerfont enabled sustained glucocorticoid reductions to physiologic range in adults with classic congenital adrenal hyperplasia.

CAHtalyst Adult: Sustained GC Reduction With Crinecerfont in CAH, With Oksana Hamidi, DO

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Triple therapy with budesonide–glycopyrronium–formoterol fumarate (BGF) was associated with statistically significant improvements in lung function and reductions in severe exacerbations among patients with 

 despite inhaled corticosteroid–long-acting β2-agonist (ICS–LABA) therapy, according to results from the phase 3 KALOS and LOGOS trials.

Current Global Initiative for Asthma (GINA) recommendations support escalation to triple therapy with ICS–LABA–LAMA in patients with uncontrolled disease at step 5, particularly those with exacerbation risk.

 However, real-world uptake and optimal patient selection remain areas of ongoing investigation.

Alberto Papi, MD, from the University of Ferrara in Italy, Robert A. Wise, MD, from Johns Hopkins University, and colleagues conducted the KALOS and LOGOS trials: 2 multicenter, randomized, double-blind, double-dummy, parallel-group phase 3 studies enrolling patients aged 12 to 80 years with asthma inadequately controlled on medium- or high-dose ICS–LABA therapy.

 Participants were randomized to receive 1 of 4 regimens: BGF 320/28.8/10 μg, BGF 320/14.4/10 μg, budesonide–formoterol fumarate dihydrate via Aerosphere (BFFA), or budesonide–formoterol suspension (BFFS), administered twice daily for 24 to 52 weeks via a pressurized metered-dose inhaler.

A total of 8820 participants were recruited across both trials, with 4311 receiving treatments. The primary endpoints included changes from baseline in FEV₁ area under the curve over 0–3 hours (AUC₀–₃) and morning pre-dose trough forced expiratory volume in 1 second(FEV₁) over 24 weeks, as well as pooled annualized severe exacerbation rates.

Across the pooled analysis, BGF demonstrated superiority over dual therapy comparators in both FEV₁ measures and annualized exacerbation rates.

 These findings support the addition of a long-acting muscarinic antagonist (LAMA) in patients with persistent symptoms and may inform treatment escalation strategies.

BGF 320/28.8/10 μg met all multiplicity-adjusted primary endpoints. Compared with combined dual therapy comparators, BGF improved trough FEV₁ by 76 mL (95% CI, 57–94; 

<.0001) and FEV₁ AUC₀–₃ by 90 mL (95% CI, 72–108; 

<.0001). In pooled analyses, BGF reduced severe exacerbation rates versus combined budesonide–formoterol comparators (incidence rate ratio [IRR], 0.86; 95% CI, 0.76–0.97; 

=.012) and versus BFFS alone (IRR, 0.82; 95% CI, 0.71–0.94; 

=.0043). The reduction versus BFFA did not reach statistical significance (IRR, 0.90; 95% CI, 0.78–1.03; 

Adverse events were reported in 53.2% of patients receiving BGF 28.8 μg, compared with 55.2% to 60.0% across comparator groups. No treatment-related deaths were reported, and the overall safety profile was consistent with known effects of ICS–LABA and LAMA therapies.

The addition of a LAMA targets bronchoconstriction through muscarinic receptor antagonism, complementing the anti-inflammatory effects of ICS and bronchodilation from LABA. BGF combines budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) in a pressurized metered-dose inhaler using co-suspension delivery technology. This formulation has previously been approved for chronic obstructive pulmonary disease (COPD) based on results from ETHOS and KRONOS.

 Its evaluation in asthma extends the potential role of this platform into a broader airway disease population.

Although statistically significant, the absolute improvements in FEV₁ were modest, and the clinical significance at the individual patient level may vary.

The trials included a broad population, which enhances generalizability but may obscure subgroup-specific effects, such as by eosinophilic phenotype or biomarker status. Additionally, the lack of statistically significant exacerbation reduction versus one comparator (BFFA) highlights the need for further comparative effectiveness data.

“Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS–LABA before escalation,” the team wrote.

Papi A, Wise RA, Jackson DJ, et al. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. 

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. Published 2022. Accessed on April 24, 2026. 

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. 

Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. 

Articles

Twin phase 3 randomized trials (KALOS/LOGOS) evaluated budesonide–glycopyrronium–formoterol (BGF) in adolescents and adults with asthma uncontrolled on medium/high-dose ICS–LABA. Across pooled analyses, BGF 320/28.8/10 μg achieved multiplicity-adjusted co-primary lung-function endpoints and reduced annualized severe exacerbations versus pooled budesonide–formoterol comparators, with no new safety signals. Absolute FEV₁ gains were modest, and exacerbation reduction versus one dual-therapy comparator was not statistically significant, underscoring residual uncertainty around optimal patient selection.

Twin phase 3 trials show triple therapy with budesonide–glycopyrronium–formoterol improves FEV1 and lowers severe exacerbation rates in patients with uncontrolled asthma on ICS–LABA


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

BGF Triple Therapy Improves Lung Function in Phase 3 Uncontrolled Asthma Controls

Rory Sayres, PhD, is a researcher in the Health AI group in Google Research who focuses on intelligence augmentation of medical experts using machine-learning-based assistance.

Liu and Sayres emphasize that while AI tools improve consumer recognition of skin conditions, gaps remain in prediction accuracy and information.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Patient Awareness of Dermatologic Conditions Using AI, With Rory Sayres, PhD, and Yun Liu, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A recent study presented at AACE 2026 has displayed the IGF-1R’s capacity for improving proptosis and disease activity in patients with poorly-controlled TED.

Thyroid Disorders

IBI311 Efficacious and Safe in Reducing Proptosis in Thyroid Eye Disease

Learn how Leipzig scoring and genetic testing, plus labs and eye exams, help diagnose pediatric Wilson disease when symptoms are subtle.

Video Series

Addressing Diagnostic Challenges in Wilson Disease

Experts explain how deucravacitinib eases psoriasis itch fast, boosts quality of life, and why TB testing and boxed warnings matter.

Integrating TYK2 Inhibitors into the Psoriasis Treatment Algorithm

Learn a stepwise approach to evaluating EPI-like diarrhea—history, alarm features, fecal elastase and imaging—to rule out IBS, celiac, IBD.

Navigating the Differential: When EPI Looks Like Something Else

Joseph Leventhal, MD, PhD, is a Professor of Surgery and Director of the Kidney and Pancreas Transplant Programs within the Comprehensive Transplant Center of the Northwestern University Feinberg School of Medicine.

Levanthal describes the limits of current immunosuppression and the rationale behind early-phase clinical trials evaluating cellular therapies.

Strategic Alliance Partnership

Is Transplant Tolerance the Next Frontier in Kidney Care? With Joseph Leventhal, MD, PhD

New oral psoriasis therapy delivers biologic-level skin clearance in tough patients, with PASI 100 rising to 42% by week 24.

Patient-Reported Outcomes and Safety of TYK2 Inhibitors in Psoriasis

Learn how subtle liver labs and movement changes trigger early Wilson disease testing, from newborn screening to MRI and copper assays.

Multidisciplinary Collaboration and Diagnostic Frameworks in Wilson Disease

Learn how primary care, APPs, and specialists collaborate to spot symptoms, refer fast, and follow guidelines for accurate GI diagnosis.

EPI Testing Strategies: What to Order and When

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

RCTs show intermittent fasting and calorie restriction yield similar HbA1c and cardiometabolic outcomes in type 2 diabetes, with modest, nonsignificant weight differences.

Latest News

Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD

Transplant Care Strategies to Target Mistrust, Close Gaps in Indigenous Communities

Breaking the ‘Watch and Wait’ Model in Prediabetes Care, With Scott Isaacs, MD

CAHtalyst Adult: Sustained GC Reduction With Crinecerfont in CAH, With Oksana Hamidi, DO

BGF Triple Therapy Improves Lung Function in Phase 3 Uncontrolled Asthma Controls